As a consequence, EGFR has been a subject of investigation for targeted therapies, with monoclonal antibodies and small-molecule tyrosine kinase inhibitors, exploring it as a potential therapeutic agent in ovarian carcinoma. Here, EGFR is linked to ovarian carcinoma.